RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Il fattore di trascrizione NF-kB nella regolazione del differenziamento ed apoptosi del sistema immune.
• 2 - Analisi molecolare e funzionale di IBtk, una proteina regolatrice dell'attivazione di cellule linfocitarie B.
• 3 - Il sistema GITR/GITRL nelle malattie a patogenesi autoimmunitaria/infiammatoria: un bersaglio per la terapia farmacologica
• 4 - Modulazione dei meccanismi di apoptosi in corso di risposta immunitaria/infiammatoria: studio delle interazioni tra citochine della famiglia del TNF per la caratterizzazione di meccanismi molecolari e cellulari funzionali alla identificazione di nuovi target per la terapia di malattie croniche degenerative.
• 5 - I membri della famiglia del TNF nella modulazione del differenziamento cellulare e dell'attività antitumorale
• 6 - Studio dell’integrazione tra segnali extracellulari e controllo della proliferazione e differenziamento attraverso le modificazioni postraduzionali di fattori trascrizionali chiave.
• 7 - BERSAGLI MOLECOLARI PER NUOVE TERAPIE ANTINEOPLASTICHE ATTRAVERSO LO STUDIO DI PROTEINE-SEGNALE CELLULARI E VIRALI E DI INIBITORI SPECIFICI
• 8 - Identificazione di nuovi meccanismi molecolari dei glucocorticoidi nella regolazione di geni coinvolti nei processi infiammatori.
• 9 - CONTROLLO DEL CICLO CELLULARE DA LIGANDI DI RECETTORI NUCLEARI
• 10 - Ruolo, Meccanismi molecolari e nuovi interattori delle proteine Prep/Meis/Pbx nello sviluppo embrionale.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
  • BIOLOGIA MOLECOLARE
  • GENETICA
• Area scientifico disciplinare: Scienze mediche

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Campania

Bibliografia

1) Silverman N, Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity.
Genes Dev. (2001) 15, 2321-42.
2) Verma IM et al. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. (1995) 9, 2723-35.
3) Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
Annu Rev Immunol. (2000) 18, 621-63.
4) Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. (1999) 18, 6853-66.
5) Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. (1998) 16, 225-60.
6) May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview.Semin Cancer Biol. (1997) 8, 63-73.
7) Beg AA, et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. (1995) 376, 167-70.
8) Doi TS, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci U S A. (1999) 96, 2994-9.
9) Doi TS et al. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med. (1997) 185, 953-61.
10) Sha WC, et al. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell (1995) 80, 321-30.
11) Grumont RJ et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells.J Exp Med. (1998) 187, 663-74.
12) Ishikawa H et al. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50. J Exp Med. (1998) 187, 985-96.
13) Weih F, Carrasco D, Bravo R. Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen. Oncogene. (1994) 9, 3289-97.
14) Franzoso G et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med. (1998) 187, 147-59.
15) Burkly L, et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature. (1995) 373, 531-6.
16) Weih F et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell. (1995) 80, 331-40.
17) Kontgen F,et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. (1995) 9, 1965-77.
18) Franzoso G et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. (1997) 11, 3482-96.
19) Senftleben U et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. (2001) 293, 1495-9.
20) Dejardin E et al The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity. (2002) 17, 525-35.
21) Kayagaki N et al BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. (2002) 17, 515-24.
22) Claudio E, et al. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. (2002) 3, 958-65.
23) Tanaka M et al Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity. (1999) 10, 421-9.
24) Li ZW, et al The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis J Exp Med. (1999) 189, 1839-45.
25) Li Q, et al. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science. (1999) 284, 321-5.
26) Hu Y, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science. (1999) 284, 316-20.
27) Li Q, et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. (1999) 13, 1322-8.
28) Takeda K, et al. Limb and skin abnormalities in mice lacking IKKalpha. Science. (1999) 284, 313-6.
29) Hu Y, et al IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature. (2001) 410, 710-4.
30) Yamaoka S, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell. (1998) 93,1231-40.
31) Harhaj EW, et al. Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein. Oncogene. (2000) 19, 1448-56.
32) Rudolph D, et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. (2000) 14, 854-62.
33) Smahi A, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. (2000) 405, 466-72.
34) Doffinger R, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet. (2001) 27, 277-85.
35) Leonardi A, et al. CIKS, a connection to Ikappa B kinase and stress-activated protein kinase.Proc Natl Acad Sci U S A. 82000) 97, 10494-9.
36) Chariot A, et al. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes
with IKK epsilon and TBK1 kinases. J Biol Chem. (2002) 277, 37029-36.
37) Hahm, K., Ernst, P., Kim, G:S:, Turck, C:, Smale,ST. (1994) Mol.Cell.Biol., 14, 7111-7123
38) Molnar,A., Georgopoulos, K., (1994) Mol: Cell. Biol 14, 585-592
39) Morgan, B., Sun, L., Avitahl, N., (1997) 16, 2004-2013
40) Hahm, K., Cobb, BS., McCarty, AS. (1998) Genes Dev., 12, 782-796
41) Winandy, S.,Wu,P., Georgopoulos, K., (1995) Cell 83, 289-299
42) Wang, J., Nichogiannopoulos, A., Wu,L. (1996) Immunity 5, 537-549
43) Wang, J., Avitahl, N., Cariappa, A. (1998) Immunity 9, 543-553
44) Nakase,K., Ishimaru, F., Fujii, K. (2002) Exp. Hematol. 30,313-317
45) Han, Z.G., Zhang, Q.H., Ye, M., Kan, L.X., Gu, B.W., He, K.H., Shi, S.L., Zhou, J., Fu, G., Mao, M., Chen. S.J., Yu, L., Chen, Z., (1999) J. Biol. Chem. 274, 35741-35748
46) Lee, T.H., Lwu, S., Kim, J., and Pelletier, J (2002) J. Biol. Chem. 277, 44826-44837

Parole Chiave

RISPOSTA IMMUNE; TRASCRIZIONE; PROLIFERAZIONE; APOPTOSI; TRASDUZIONE DEL SEGNALE; NF-KB; LEUCEMIA; INFIAMMAZIONE